Nelkarmi Wins Accelerated FDA Approval for ALK-Positive Lung Cancer That Progressed After Alectinib or Two Earlier Drugs
GSK's Nelkarmi (neladalkib) received FDA accelerated approval for advanced ALK-positive lung cancer after prior treatments. Approval based on trial data showing tumor shrinkage in 49% (alectinib-only) and 32% (multiple treatments). GSK acquired developer Nuvalent. Confirmatory trial required for continued approval.
How this was made

The 30-second read
Why it matters
The article frames the approval as response-rate driven (not yet survival benefit) and highlights confirmatory-trial dependence, plus liver enzyme elevation as the main safety concern.
Market read
Traders can reassess oncology pipeline value and confirmatory-trial risk for the sponsor and developer following a new FDA approval with quantified response and safety data.
What to watch
Safety burden (notably ALT elevations) and the lack of disclosed pricing could limit uptake and near-term revenue expectations despite the regulatory win.
Background
The FDA granted accelerated approval to neladalkib (Nelkarmi) for adults with advanced ALK-positive non-small cell lung cancer that progressed after earlier targeted treatment, based on ALKOVE-1 tumor response.
Ticker impact
GSK announced FDA accelerated approval of Nelkarmi (neladalkib), adding a new ALK-positive lung cancer option ahead of the FDA target date.
Likely modest-to-positive reaction as the market incorporates a new regulatory asset, with caution around confirmatory trial outcomes.
The piece provides the approval scope, trial basis (ALKOVE-1), and key safety signals, but does not include pricing or sales guidance, limiting magnitude certainty.
Market effects
Reinforces investor focus on ALK-positive NSCLC targeted therapies and the market’s willingness to reward accelerated approvals tied to tumor response.
Primarily impacts US-listed biotech and large-cap pharma sentiment tied to FDA oncology approvals.
Supports global oncology M&A and licensing expectations around ALK inhibitors, especially those with brain-penetration claims.
Counterpoint
Because this is accelerated approval based on tumor shrinkage without overall survival data, the market may fade the initial optimism if confirmatory trial signals are weaker.
Key entities
- drugNelkarmi (neladalkib)
ALK-selective therapy for advanced ALK-positive NSCLC, approved under accelerated approval.
- clinical_trialALKOVE-1
Single-arm Phase 1/2 trial supporting the accelerated approval.
- companyGSK
Announced the FDA accelerated approval and acquired Nuvalent.
- companyNuvalent
Developed neladalkib (Nelkarmi) and is now part of GSK.
- regulatorFDA
Granted accelerated approval and set a confirmatory requirement for continued indication.




